BioGaia AB (LTS:0GTN) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GTN BioGaia AB LTS:0GTN
95 GF Score
Price kr115.51
GF Value kr127.39
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioGaia AB FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0GTN
95GF Score
BioGaia AB LTS:0GTN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioGaia AB (LTS:0GTN) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of kr115.51 is trading 9.3% below its estimated GF Value™ of kr127.39. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for LTS:0GTN:

  • FFO:
  • GF Value™: kr127.39 vs. price of kr115.51 (9.3% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the LTS:0GTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Other Exchanges BIOG B:SwedenBGLA:Germany
Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
95GF Score

Get the complete analysis for LTS:0GTN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr115.51
Price
kr127.39
GF Value